Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) Research & Development (2018 - 2025)

UroGen Pharma (URGN) has disclosed Research & Development for 8 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 3.89% year-over-year to $14.3 million, compared with a TTM value of $67.1 million through Dec 2025, up 17.43%, and an annual FY2025 reading of $67.1 million, up 17.43% over the prior year.
  • Research & Development was $14.3 million for Q4 2025 at UroGen Pharma, up from $14.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $19.9 million in Q1 2025 and bottomed at $10.2 million in Q3 2023.
  • Average Research & Development over 5 years is $13.5 million, with a median of $12.9 million recorded in 2021.
  • Peak annual rise in Research & Development hit 49.57% in 2021, while the deepest fall reached 36.62% in 2021.
  • Year by year, Research & Development stood at $13.1 million in 2021, then increased by 10.66% to $14.5 million in 2022, then decreased by 21.93% to $11.3 million in 2023, then soared by 31.78% to $14.9 million in 2024, then dropped by 3.89% to $14.3 million in 2025.
  • Business Quant data shows Research & Development for URGN at $14.3 million in Q4 2025, $14.0 million in Q3 2025, and $18.9 million in Q2 2025.